A Traditional Chinese Herbal Medicine for OB/GYN. Written in the Eastern Han Dynasty text Essential Prescriptions of the Golden Chest (220 A.D.). Monthly Ease common American name,, Keishi-bukuryo-gan in Japanese and Gui Zhi Fu Ling in Chinese. Cinnamon and Hoelen another common English name. A very popular and safe herbal tea.
This formula is classical for ovarian cysts and breast lumps. (Phlegm Stagnation). Also for For phlegm or blood stagnation in genital area, especially female. If painful to touch, mass or irreg menses, difficult labor, or postnatal placenta probs (not expelled). Pregnancy with Blood Stasis in Womb resulting in chronic mischarage: Bleeding Mild, persistent uterine bleeding of purple or dark blood during pregnancy accompanied by abdominal pain that increases with pressure. Also for such problems as immobile masses in the lower abdomen with pain and tenderness, abdominal spasms and tension, amenorrhea with abdominal distention and pain, dysmenorrhea, and retention of the lochia. All disorders are accompanied by a choppy pulse. Tongue: Slightly, purple, white coat
Physical Indications: In Chinese medicine, Blood is a dense, material form of qi and, as such, needs to flow evenly and regularly; its movement should never be forced or erratic. If the smooth flow of Blood is blocked, a condition of congealed Blood may result. Congealed Blood often results as gynecological complaints such as uterine fibroids, ovarian cysts, chronic pelvic inflammatory disease, endometriosis, and post-partum retention of lochia. Women's Chamber is especially useful when congealed Blood causes palpable masses in the lower abdomen, which may be accompanied by pain and tenderness.
On a circulatory level, congealed Blood can manifest as chronic numbness in the limbs, chronic skin problems, and chronic chest pain. Therefore, Women's Chamber is a suitable formula for women or men who present these types of conditions.
Chinese medicine considers Blood to be the aspect of ourselves that allows our behavior and activities to flow comfortably and smoothly; it allows us to feel rooted and to have a sense of our place in the world. Conversely, congealed Blood can cause feelings of terror, disconnection from oneself, and paranoia. Women's Chamber can help alleviate such emotional imbalances and restore a sense of stability.
Pharmacotherapeutic effects of on human uterine myomas.
Sakamoto S, Yoshino H, Shirahata Y, Shimodairo K, Okamoto R.
Medical Research Institute, Tokyo Medical and Dental University, Japan.
frequently used in the treatment of gynecological disorders such as hypermenorrhea, dysmenorrhea and sterility. We previously reported that KBG might act as a LH-RH antagonist and a weak anti-estrogen on the uterine DNA synthesis in immature rats. In the present study, we investigated the effects of KBG on 110 premenopausal patients with uterine myomas. Clinical symptoms of hypermenorrhea and dysmenorrhea were improved in more than 90% of the cases with shrinking of uterine myomas in roughly 60% of the cases.
Applications: Leiomyoma (Uterine fibroid), primary dysmenorrhea, cervical erosion, ovarian cysts, chronic salpingitis, chronic pelvic inflammatory disease, endometriosis, lochioschesis. Pain management, PMS, Endometriosis, adenomyosis, leiomyoma Hypermenorrhea , functional dysmenorrhea, organic dysmenorrhea, Polycystic ovary, Atherosclerosis, infertility,
It can also be used by men for prostate problems.and hemmroids.
And also helpful for both sexes in relieving emotional trauma when there is a sense internal disconnect.
This study tests to see if TU 025 Keishi Bukuryo Gan reduces the frequency and severity of hot flashes in post-menopausal American women. This study will also estimate the best dose amount and determine the common short-term side effects and risks.
Menopause is a natural transition in a woman's hormonal state associated with the cessation of ovulation and menstruation. For approximately 80% of peri-menopausal women, menopause may be defined by the experience of uncomfortable symptoms such as hot flashes, night sweats, dyspareunia, urinary frequency, sleep disturbance, fatigue, depression and anxiety.
Hot flashes are the most common complaint of perimenopausal and postmenopausal Western women. Approximately 10-20% of postmenopausal women find such symptoms nearly intolerable. Nearly one-third of postmenopausal women experience disruptive hot flashes for 5 years after natural menopause and approximately 20% experience hot flashes for 15 years.
Menopause has been understood as an estrogen deficiency state from which women are placed at great risk for osteoporosis, colon cancer and heart disease. For symptom management, as well as for disease prevention, the medical response for 20 years has been hormone replacement therapy (HRT). In recent years, as many as 38% of US women between ages 50 and 74 years were using HRT.
For menopause hormone therapy, in 2005, counseling patients from an evidence-based perspective means informing patients of the significantly increased risk of dementia, breast cancer,endometrial cancer,venous thromboembolism and gallbladder disease. Additionally, physicians must also state that hormone therapy increases the risk of cardiovascular events (heart attack or strokes) in women with or without pre-existing heart disease. Furthermore, well-done studies demonstrate that hormone therapy does not enhance health-related quality of life.
For this reason, there is great interest in non-hormonal alternatives for menopausal hot flash management. The current standard of care, based on controlled clinical trials in women with breast cancer, is the use of SSRI anti-depressants such as venlafaxine. However, many women seek other options.
In Japan, TJ25 Keishi Bukuryo Gan is a leading non-hormonal prescription agent for management of menopausal hot flashes. However, no clinical data exists on its effectiveness in American women.
This is a pilot phase II clinical study to estimate the effectiveness of TU-25 Keishi Bukuryo Gan for reduction of both the severity and the frequency of hot flashes in healthy postmenopausal American women. This study will also estimate the best dose and determine the common short-term side effects and risks.
University of Minnesota General Clinical Research Center
Minneapolis, Minnesota, United States, 55455
ClinicalTrials.gov identifier: NCT00119418
Keishi-bukuryo-gan (Gui-Zhi-Fu-Ling-Wan) (KBG) is one of the prescriptions in Japanese traditional medicine for improving the "oketsu" syndrome, so-called blood stasis syndrome. "Oketsu" syndrome is an important pathological conception in Japanese traditional medicine and often accompanies cerebro-vascular disorders. Previously, we were able to reveal a deterioration of RBC (Red blood cell) deformability and viscoelasticity in patients with "oketsu" syndrome. The purpose of the present study was to evaluate whether KBG has an effect on RBC deformability in comparison with pentoxifylline (PXF). The subjects were 30 male patients with multiple lacunar infarctions. Eighteen patients (44-79 yrs, mean +/- SD, 66.1 +/- 10.7 yrs) were treated with 12 g of KBG daily for 4 weeks (KBG group). Twelve patients (59-78 yrs, 70.7 +/- 6.4 yrs) were treated with 300 mg of PXF daily for 4 weeks (PXF group). Based on the "oketsu" score, the patients of each group were divided into two subgroups, a non-"oketsu" group ("oketsu" score 20 points or less) and an "oketsu" group ("oketsu" score 21 points or higher). KBG had significant effects on RBC deformability as evaluated by filtration method. KBG also significantly increased intracellular ATP content, as did PXF. Moreover, KBG was more effective for patients with a more severe "oketsu" state. However, PXF was effective only in patients with "oketsu" syndrome, who might have deteriorated RBC deformability. In conclusion, the effect of KBG on RBC deformability was by no means inferior to PXF
Keishi-bukuryo-gan (TJ-25) is a traditional Chinese herbal remedy containing five components: bark of Cinnamomum cassia, root of Paeonia lactiflora, seed of Prunus persica or P. persiba var. davidiana, carpophores of Poria cocos and root bark of Paeonia suffruticosa. This preparation has been used in the treatment of gynecological disorders such as hypermenorrhea, dysmenorrhea and infertility. In the present study, the effects of TJ-25 on plasma levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and estradiol (E2), and on uterine wet weight and thymidine kinase (TK) activity were documented in immature rats. Long-term daily oral administration of TJ-25 (300 mg/kg) for 14 days decreased plasma levels of LH, FSH and E2 by 94%, 67% and 50%, respectively, compared to controls. Uterine wet weight and TK activity were reduced to 65% and 64% that of controls, respectively. Short-term effects of TJ-25 on E2 were also examined. Thirty hours after administration of E2 (1.0 micrograms/kg) alone, uterine wet weight and TK activity were elevated 2.4- and 21-fold, respectively, over controls. However, simultaneous administration of TJ-25 (three consecutive doses, every 12 h) with E2 reduced E2-induced increases in uterine wet weight and TK activity by 29% and 39%, respectively. Treatment with TJ-25 also enhanced LH-RH-induced increases in plasma LH and FSH levels 1.2- and 2.5-fold, respectively, as compared with controls. The results obtained in the present study indicate that TJ-25 may act as a LH-RH antagonist and/or as a weak anti-estrogen.